what is oral semaglutide semaglutide: it and how do you take it? Semaglutide Tablets

- MASH affects 6% of US adults - Linked to liver cancer, transplant risk, and cardiometabolic complications - First approved therapy targeting both metabolic dysfunction and fibrotic progression Clinical Implications - Early intervention now has a validated pharmacologic option - Opens doors for multidisciplinary care across hepatology, endocrinology, and primary care - Reinforces the role of GLP-1 therapies beyond diabetes and obesity Your Voice Matters: How will semaglutides approval reshape your approach to managing MASH and liver fibrosisespecially in high-risk or underserved populations

Given the significant effect of time and our interest in the effects of the IF-P group, we prepared a GLM with age, sex, BMI, and time as covariates and corrected for FDR (Figure 5A)

2012;303(4):R422-R431

| University of Utah Health